Business
HLS Therapeutics Highlights Latest Icosapent Ethyl Research Presented at the Canadian Cardiovascular Congress
HLS Therapeutics Highlights Latest Icosapent Ethyl Research Presented at the Canadian Car...
About this update from Hls Therapeutics, Inc.
[{"type":"text","content":"\n \n \n \n HLS Therapeutics Highlights Latest Icosapent Ethyl Research Presented at the Canadian Cardiovascular Congress\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n TORONTO, Oct. 22, 2020\n \n \n \n \n \n \n \n In vitro data presented provides additional insight into potential mechanisms by which Vascepa reduces cardiovascular risk\n \n \n \n \n \n \n TORONTO\n \n ,\n \n Oct. 22, 2020\n \n /CNW/ - \"The Vascepa story continues to unfold as we learn more about how icosapent ethyl acts on a cellular level,\" said\n \n Gilbert Godin\n \n , President and CEO of HLS Therapeutics. \"The new in vitro data presented at CCC may help us to further understand the possible ways by which Vascepa works.\"\n \n \n Vascepa is indicated to reduce the risk of cardiovascular events\n \n 4\n \n , in statin-treated patients with elevated triglycerides with established cardiovascular disease, or diabetes, and at least one other cardiovascular risk factor. The three poster presentations contribute novel insights into icosapent ethyl that include:\n \n \n \n Icosapent ethyl reduces cellular inflammation\n \n 1\n \n , which may be a factor in plaque regression in the arteries as seen in the EVAPORATE\n \n 5\n \n trial that enrolled both diabetic and non-diabetic high-risk patients.\n \n \n Icosapent ethyl may improve the activity of human blood vessels, compared to the impact from other omega-3 fatty acids\n \n 2\n \n .  These vascular benefits of icosapent ethyl may potentially lead to reduced clot formation and plaque stabilization.\n \n \n Icosapent ethyl and statins may work hand-in-hand to reduce oxidative stress, inflammation and cholesterol removal from the cells through preserved HDL, or \"good cholesterol\", function.\n \n 3\n \n \n \n \n Also featured in the Canadian and International Perspectives on late breaking Clinical Trials at the CCC will be a presentation on Vascepa's landmark REDUCE IT trial\n \n 6\n \n by Dr. Deepak L. Bhatt MD MPH, Executive Director of Interventional Cardiovascular Programs at Brigham an...